Open orange pill bottle with rounded white pills
What’s the Evidence for Fluvoxamine in COVID-19? 
The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.
ABOVE: © iStock.com, AndrewSoundarajan
What’s the Evidence for Fluvoxamine in COVID-19? 
What’s the Evidence for Fluvoxamine in COVID-19? 

The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.

The US FDA’s decision not to grant an emergency use authorization for the antidepressant as a COVID-19 treatment highlights a lack of consensus among researchers about how to interpret clinical data on the drug.

ABOVE: © iStock.com, AndrewSoundarajan

Big Pharma

gene therapy approval used manipulated data
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.
FDA commissioner retires
FDA Commissioner Scott Gottlieb Announces Resignation
Jef Akst | Mar 5, 2019
Gottlieb will step down after two years at the helm of the US Food and Drug Administration to spend more time with his family.
Cochrane Collaboration Expels Cofounder, Prompts Resignations
Catherine Offord | Sep 18, 2018
Physician Peter Gøtzsche, a board member of the organization, has been an outspoken critic of certain vaccines and of the pharma industry in general.
NIH Won’t Use Industry Money for Opioid Research Initiative
Shawna Williams | Apr 19, 2018
The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 22, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
Dengue Vaccine Program Halted Over Safety Issues
Shawna Williams | Dec 5, 2017
The drug may worsen future infections for people who haven't already been exposed to the virus.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion
Joshua A. Krisch | Jan 9, 2017
The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.
TS Picks: August 9, 2016
Bob Grant | Aug 9, 2016
Gene therapy money-back guarantee; the brain benefits from bilingualism; Q&A with a science watchdog
Pfizer Scoops Anacor for $5.3 Billion
Bob Grant | May 17, 2016
The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.
Bayer Enters CRISPR Field
Karen Zusi | Dec 22, 2015
The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.
Pfizer and Allergan to Merge
Bob Grant | Nov 23, 2015
The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.
Shire Buys Rare Disease Drug Developer
Tracy Vence | Nov 2, 2015
The Irish drugmaker is set to acquire the Massachusetts-based Dyax in a $5.9 billion deal.
Hearing Help
Kate Yandell | Sep 1, 2015
For decades, the only remedies for hearing loss were devices such as hearing aids or cochlear implants. Now, the first pharmaceutical treatments may be on the way.
 
Legionnaires’ Bacteria at GSK
Jef Akst | Aug 14, 2015
GlaxoSmithKline temporarily shuts down a manufacturing plant in North Carolina after Legionella bacteria are detected in two external cooling towers.
Teva Buys Allergan Generics for $40.5 Billion
Tracy Vence | Jul 27, 2015
Meanwhile, Allergan acquires drug developer Naurex in a $560 million deal. 
AbbVie Wins Bidding War for Cancer Drugmaker
Bob Grant | Mar 5, 2015
The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.
Pfizer to Acquire Hospira
Bob Grant | Feb 5, 2015
The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.
Lazarus Drugs
Kate Yandell | Feb 1, 2015
While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.